Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PE0116 + PE0105 in Advanced Solid Tumors
NCT06026501Phase 2Not yet recruiting
- Sponsor
- Yingli Pharma
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of PE0116 in solid tumor (advanced stage), ovarian cancer, Cervical Cancer (CC), renal cell carcinoma (RCC), head and neck cancer (HNC), sponsored by Yingli Pharma. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
PE0116
03
Conditions
solid tumor (advanced stage)ovarian cancerCervical Cancer (CC)renal cell carcinoma (RCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT06026501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026501.